Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axsome Therapeutics, Inc. (NASDAQ: AXSM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer focused on central nervous system (CNS) conditions, Axsome uses its SEC reports to communicate financial results, product revenue for AUVELITY, SUNOSI, and SYMBRAVO, and updates on its development pipeline, which includes programs such as AXS-05, AXS-12, AXS-14, solriamfetol in new indications, and AZD7325.
Among the filings, Form 8-K current reports are especially relevant for tracking material events. For example, Axsome has filed 8-Ks to furnish press releases announcing quarterly financial results and to disclose updates such as the receipt of a Paragraph IV Certification Notice Letter regarding a proposed generic version of SYMBRAVO. These documents help investors understand how clinical progress, intellectual property developments, and commercial performance affect the company.
In addition to 8-Ks, investors typically review Axsome’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed discussions of net product revenue, research and development spending, selling and administrative expenses, risk factors, and descriptions of the company’s CNS portfolio and pipeline. Proxy statements and, when applicable, Forms 3, 4, and 5 can provide information on insider holdings and transactions, while registration statements and prospectuses outline capital-raising activities.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-Ks, 10-Qs, and major 8-Ks in plain language. Real-time EDGAR updates help ensure that new Axsome filings appear promptly, and AI-generated highlights can make it easier to locate information on topics such as AXS-05’s regulatory status, AXS-12’s Orphan Drug Designation, or revenue trends for AUVELITY, SUNOSI, and SYMBRAVO without reading every page of the underlying filing.
Axsome Therapeutics reports that Apotex has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market a generic version of Symbravo, a meloxicam‑rizatriptan benzoate product. Axsome received a Paragraph IV certification notice from Apotex, which is a formal notification tied to generic drug applications. The company states that it plans to respond to this notice in due course, indicating the start of a potential patent and exclusivity challenge to Symbravo.
RTW Investments, LP and Roderick Wong disclose a 3.1% stake in Axsome Therapeutics. The filing reports ownership of 1,516,903 shares, calculated from 49,236,365 shares outstanding as of April 28, 2025. The shares are held directly by RTW Funds, for which RTW Investments acts as investment adviser, and Dr. Wong is identified as Managing Partner and Chief Investment Officer with shared voting and dispositive power over the reported position. The statement affirms the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Because the position is below 5%, it does not cross the threshold that typically requires more detailed disclosure of control intentions.
Axsome Therapeutics’ Q2-25 10-Q shows fast topline growth, narrower losses and a refinancing that reshapes the balance sheet.
- Revenue: Q2 product sales surged 72 % YoY to $148.9 M (Sunosi, Auvelity, launch-quarter Symbravo) lifting total revenue to $150.0 M. 1H-25 revenue rose 67 % to $271.5 M.
- Profitability: Q2 operating loss narrowed to $36.7 M vs. $78.0 M; net loss improved to $48.0 M (-$0.97/sh) from $79.3 M (-$1.67/sh). 1H net loss was $107.4 M. Gross margin remained high (cost of product 9 % of sales).
- Expenses: SG&A climbed 26 % YoY to $130.3 M (marketing for three brands); R&D essentially flat at $49.5 M. Advertising spend YTD $63.7 M.
- Cash & liquidity: Cash/cash equivalents $303.0 M (-$12.3 M YTD). Operating cash burn $75.8 M, improved vs. $83.6 M prior year.
- Capital structure: May 2025 Blackstone facility (up to $570 M) replaced Hercules debt. At 6-30-25: $120 M term loan (9.6 % SOFR+4.75%) and $70 M revolver (SOFR+4.0%) drawn; long-term debt net of discount $117.5 M (down from $180.7 M). Loss on extinguishment $10.4 M recorded.
- Equity: Shares outstanding 49.9 M (+2 % YTD). Stockholders’ equity up to $73.1 M from $57.0 M.
- Outlook: Management believes current cash covers operations ≥12 months while commercialization spending rises for Auvelity, Sunosi and newly launched Symbravo.
Key takeaways: Rapid revenue expansion and refinancing reduce financing risk, but sustained operating losses, heavy SG&A and rising receivables remain watch points.
Hunter R. Murdock, General Counsel of Axsome Therapeutics (AXSM), executed multiple stock option exercises and sales under a pre-approved 10b5-1 plan:
- On June 20, 2025: Exercised 7,500 stock options at $29.91 and immediately sold the shares at an average price of $102.47, realizing approximately $544,200 in gross proceeds
- On June 23, 2025: Exercised 6,014 stock options at $29.91 and sold at an average price of $100.12, generating approximately $421,700 in gross proceeds
Following these transactions, Murdock retains 16,369 stock options exercisable until March 4, 2032. The trades were executed through a completed 10b5-1 trading plan, which provides a safe harbor from insider trading allegations by pre-scheduling trades. The significant spread between exercise price ($29.91) and sale prices ($100-103) indicates substantial share price appreciation since the option grant date.
Form 144 Notice Filing for Axsome Therapeutics (NASDAQ: AXSM) details proposed sale of securities by insider Hunter R. Murdock. The filing indicates a planned sale of 6,014 shares of common stock with an aggregate market value of $602,101, to be executed through Charles Schwab & Co.
The shares were acquired through an Employee Stock Option Exercise on June 23, 2025, with payment made via a cashless exercise through broker. The filing reveals significant recent insider trading activity by the same individual over the past three months:
- June 20, 2025: 7,500 shares sold for $768,503
- June 18, 2025: 7,500 shares sold for $756,729
- June 17, 2025: 7,500 shares sold for $751,975
- June 16, 2025: 7,500 shares sold for $768,154
Total outstanding shares reported: 49,236,365. The proposed sale represents a continuation of systematic insider selling pattern, with approximately 30,000 shares sold in the preceding month.
Form 144 Notice filed by Axsome Therapeutics (NASDAQ: AXSM) on June 28, 2025, detailing proposed securities sales under Rule 144. The filing indicates planned sale of 7,500 shares of common stock with an aggregate market value of $768,503 through Charles Schwab & Co.
Key transaction details:
- Securities acquired through employee stock option exercise on June 20, 2025
- Payment made via broker payment for cashless exercise
- Total shares outstanding: 49,236,365
- Planned sale date: June 20, 2025
The filing also discloses previous sales by Hunter R. Murdock in the past 3 months totaling 22,500 shares across three transactions from June 16-18, 2025, with gross proceeds ranging from $751,975 to $768,154. The seller represents no knowledge of undisclosed material adverse information regarding the issuer.
Hunter R. Murdock, General Counsel of Axsome Therapeutics (AXSM), executed a series of pre-planned transactions under a 10b5-1 trading plan over three consecutive days from June 16-18, 2025.
The transactions followed a consistent pattern each day:
- Exercised 7,500 stock options at $29.91 per share
- Immediately sold 7,500 shares at weighted average prices between $100.26-$102.42
Total transaction summary:
- Exercised: 22,500 options
- Sold: 22,500 shares
- Remaining options: 29,883
- Net proceeds per share: approximately $70-72 (sale price minus exercise price)
These transactions were executed according to a pre-approved trading plan, which helps protect executives from insider trading allegations by establishing trade parameters in advance.
Form 144 Notice of Proposed Sale filed for Axsome Therapeutics (NASDAQ: AXSM) details insider trading activity. The filing indicates a proposed sale of 7,500 shares of common stock with an aggregate market value of $756,729, to be executed through Charles Schwab & Co.
The securities were acquired through an employee stock option exercise on June 18, 2025, with payment made via a cashless exercise through broker payment. The filing reveals recent trading activity by the same insider, Hunter R. Murdock, who sold:
- 7,500 shares on June 16, 2025, generating proceeds of $768,154
- 7,500 shares on June 17, 2025, generating proceeds of $751,975
The company currently has 49,236,365 shares outstanding. This Form 144 represents the seller's declaration that they are unaware of any material adverse non-public information regarding the company's operations.